Zhejiang East Asia Pharmaceutical Co., Ltd. Class A

Zhejiang East Asia Pharmaceutical Co., Ltd. Class A

SSSE:605177
17.22
CNY
-0.61
(-3.42%)
-1.16EPS
1.96BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A carries a market capitalization of 1.96B, placing it among publicly traded companies globally. Its enterprise value stands at 2.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.96B
Enterprise Value2.57B

Important Dates

Zhejiang East Asia Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A has 114.72M shares outstanding.

Shares Outstanding114.72M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 1.87, and the price-to-book ratio stands at 1.15.

PS Ratio1.87
PB Ratio1.15
P/TBV Ratio1.23

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.57B versus a market cap of 1.96B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.48

Financial Position

As of June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.10, indicating elevated leverage, while an interest coverage ratio of -5.37 demonstrates limited ability to service its debt obligations.

Current Ratio1.97
Quick Ratio0.64
Debt / Equity54.10
Debt / EBITDA-6.02
Interest Coverage-5.37

Financial Efficiency

CNY

Over the twelve months ended June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -8.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.63, reflecting losses generated across the asset base. The company generates approximately 658,034.07 in revenue per employee across its workforce of 1,572.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.34 indicates how many times Zhejiang East Asia Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-8.49
Return on Assets (ROA)-4.63
Revenue Per Employee658,034.07
Employee Count1,572.75
Inventory Turnover1.34

Taxes

CNY

Over the twelve months ended June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -8.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -159.82M and -151.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-8.14M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A's stock has declined approximately 19.72% over the past 52 weeks. The 50-day moving average sits at 22.73, while the 200-day moving average is 20.70.

52-Week Price Change-19.72%
50-Day Moving Average22.73
200-Day Moving Average20.70

Income Statement

CNY

Over the twelve months ended June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A generated 1.03B in revenue and converted that into -151.67M in net income, yielding earnings per share of -1.16. EBITDA reached -153.13M, while operating income came in at -27.82M.

Revenue1.03B
Gross Profit236.46M
Operating Income-27.82M
Pretax Income-159.82M
Net Income-151.67M
EBITDA-153.13M
EBIT-153.13M
Earnings Per Share (EPS)-1.16

Balance Sheet

CNY

As of June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A holds 315.03M in cash and equivalents against 921.63M in total debt, resulting in a net debt position of 634.27M. Total book value stands at 1.70B, with working capital of 480.61M providing operational flexibility.

Cash & Cash Equivalents315.03M
Total Debt921.63M
Net Debt634.27M
Equity (Book Value)1.70B
Book Value Per Share14.85
Working Capital480.61M

Cash Flow

CNY

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-39.70M

Margins

Over the twelve months ended June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A posted a gross margin of 22.85, reflecting its pricing power and cost economics. The operating margin of -2.69 and net profit margin of -14.66 provide insight into operational efficiency.

Gross Margin22.85
Operating Margin-2.69
Pretax Margin-15.44
Profit Margin-14.66
EBITDA Margin-14.80

Dividends & Yields

CNY

Over the twelve months ended June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A paid dividends of 0.06 per share. The dividend payout ratio of -4.39 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang East Asia Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.06
Payout Ratio-4.39
Shareholder Yield0.12

Scores

As of June 30, 2026, Zhejiang East Asia Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 1.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.52